病死率

病死率

病死率是指在一定时期内，因患某种疾病死亡的人或动物数量占患病人或动物总数的比例，用于描述某种特定疾病的严重程度。2020年2月4日，国家卫生健康委宣布，截至2月3日晚24时，新冠肺炎全国病死率控制在2.1%，病死率低于SARS（全球病死率近11%），高于甲流（1%~1.5%）。2月24日晚，中国—世界卫生组织新冠肺炎联合专家考察组在新闻发布会上表示，新冠肺炎的轻症、重症、危重三类患者分别在80%、13%和6%左右，全国病死率约在3%~4%之间，除武汉之外，全国病死率为0.7%；截至2月20日，新冠肺炎确诊病例平均年龄为51岁，80%的病例年龄在30岁至69岁之间，78%的病例来自于湖北。

随着中医药、磷酸氯喹、恢复期血浆治疗纳入诊疗方案，法匹拉韦、瑞德西韦等药物进入临床试验阶段，新冠肺炎治疗不断取得多项进展。科技部副部长徐南平表示，目前正在多路线部署疫苗研发，部分已进入动物试验阶段，最快将于4月下旬申报临床试验。

Case Fatality Rate

The case fatality rate refers to the proportion of people or animals who die from a disease to the total number of patients or animals suffering the disease within a certain period of time, which is used to describe the severity of a particular disease. 

On February 4, the NHC announced that by 24:00 of February 3, the case fatality rate of COVID-19 in China had been controlled at 2.1%, which was lower than that of SARS (with a global case fatality rate of 11%) and higher than that of H1N1 (1%-1.5%). 

On the evening of February 24, the WHO-China Joint Mission on COVID-19 announced at its news conference that, approximately 80% of laboratory confirmed patients had mild to moderate diseases, 13.8% had severe disease and 6.1% were critical, and the case fatality rate in China was 3% to 4%, 0.7% with the exception of Wuhan; and as of February 20, the median age of confirmed cases was 51, with 80% of cases aged between 30-69 years, and 78% were from Hubei.

With traditional Chinese medicine, chloroquine phosphate, convalescent plasma therapy adopted into the diagnosis and treatment guidelines, and with Favipiravir, Remdesivir and other drugs heading into the phase of clinical research, sustainable progress has been made in the treatment of COVID-19. Xu Nanping, vice minister of science and technology, said that the vaccine is currently being developed in multiple approaches, some of which have entered animal testing phases and will be submitted for clinical trials as early as late April.